Metastat Inc · OTC:MTST
Metastat — Investor Presentation (February 2015)
28 slides from Metastat's investor presentation, Feb 26, 2015
Slide 1: MetaStat, Inc. Corporate Presentation Winter 2015
MetaStat, Inc. Corporate Presentation Winter 2015 @MetaStat
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the safe har
Slide 3: MetaStat, Inc. Company Profile
MetaStat, Inc. Company Profile Who we are: * publicly-traded (OTCOB:MTST) pre-commercial molecular diagnostic and digital pathology company; + Experienced Senior Management team and Board of Directors; + SAB made up of leading experts and oncologists from Albert Einstein College of Medicine, Massach
Slide 4: Investment Highlights
Investment Highlights Our Central Discovery - Diagnostic Platform using Epigenetic Markers to Predict the Risk of Distant Metastasis * Epigenetic understanding of the complexity of the metastatic process; * This complexity highlights the need for mechanism-based diagnostics; * Mena protein isoforms
Slide 5: Recent Developments & Company Highlights
Recent Developments & Company Highlights 1) Core technology patents issued (late 2013 and 2014) 2) ‘peri and alization team (Q1-Q2’14) + New seior management and Directors, aed ey opinion leaders to SAB 3) Closed $5.7 million financing and note conversion (July 2014) + Eliminated debt and cleaned-up
Slide 6: 2015 Company Milestone Guidance
2015 Company Milestone Guidance Assay Method Development and Analytical Validation Assay development & analytical validation —14'/2015 Clinical Development Program + Initiation of Kaiser Cohort Validation study ~ 14'15, + Initiation of ECOG 2187 Cohort study ~1H'15 Initiation of chemo-predictive stu
Slide 7: Market Opportunity: Breast Cancer Diagnostics
Market Opportunity: Breast Cancer Diagnostics ASCO & NCCN recommend breast cancer diagnostic testing for all patients* However, the current genomic tests on the market (est. to be $250-$275 million) have limited applicability; + Inherent problems with tests based on bio-statistically derived algorit
Slide 8: A $627 million annual market opportunity
A $627 million annual market opportunity for MetaStat’s diagnostic products in the U.S. Number of new | Addressable | Potentialcases | Market Size Product cases per year Market , % per year ($ mm) Mena - Breast 232,670 80 186,136 $271 MenaCalc - Lung 224,201 51 114,347 $107 MenaCale - Prostate 233,3
Slide 9: The Metastatic Cancer Problem
The Metastatic Cancer Problem MEDICAL FACT #1: systemic metastasis is responsible for 90% of solid tumor cancer related deaths MEDICAL FACT #2: Only 30-35% of breast cancer epithelial-based solid tumors are biologically capable of metastatic spread (depending upon the tumor micro-environment and the
Slide 10: The MetaStat Solution: Superior Diagnostics with Actionable Information
The MetaStat Solution: Superior Diagnostics with Actionable Information Metastat’s products have the potential to: MetaStat is poised for rapid commercialization Minimize treatment for patients with low-risk indolent tumors; Maximally treat patients with aggressive tumors; Facilitate personalized an
Slide 11: Diagnostic Product Portfolio
Diagnostic Product Portfolio MetaStat is developing a platform with multiple diagnostic applications proouct erooucrnve | cace® | bescrierion ‘Metasite Breast™ metastasis based on the density of Diagnostics | Breast “Metasites” Immunohistocheristry test Diagnostic | Breast ‘A diagnostic platform tha
Slide 12: MetaSite and MenaCalc will easily fit into existing clinical workflow
MetaSite and MenaCalc will easily fit into existing clinical workflow with a 3-5 Day turn-around time “current Werkiiow Presents Suspicious Lesion Biopsied Lesion or Excised Tissue Sample Sent Patient > Physician 7% | ratooeviab |, sstorins r? & = Provides Treatment Treatment Options & Diagnostic Re
Slide 13: Competitive Landscape
Competitive Landscape product | company | moa sssay ehitant | Aawowt | ree” | <Atertt | nevnue omcnmeoxt | irtin | “pone! | “Caresont” | nema. | tape | 8550 | aspszsoo | S260M mannan | samae | TET | sagttcrcion | te | ne | mm Jastioone | wa rodent | timosing | S26e0¢ | atorminana | et | 30 | sop sta
Slide 14: Experienced senior management team
Experienced senior management team with deep understanding of the clinical, scientific, and business aspects of oncology Management Team Name le Experience ‘Oscar ‘chief Executive * Diplomat, American Board of Surgery Bronsther, M.D. | Officer and chief | + Clinical Professor of Surgery, George Wash
Slide 15: Board of Directors with significant business, capital markets and commercial experience
Board of Directors with significant business, capital markets and commercial experience Board of Directors Name Title ‘Oscar ‘chief Executive * Diplomat, American Board of Surgery Bronsther, M.D. | Officer and chief | + Clinical Professor of Surgery, George Washington University Medical ofcer; | + F
Slide 16: Leading Scientific and Clinical Advisory Board Members
Leading Scientific and Clinical Advisory Board Members Scientific and Clinical Advisory Board - Diagnostics ‘Name Institutional Affiliation ohn S.Condealis, |» Albert Einstein College of Medicine Pho. ‘+The judith and Burton P. Resnick Charin Translational Research 1 Professor and Co-Chair of Anatom
Slide 17: Reimbursement
Reimbursement Reimbursement. * MetaSite Breast and MenaCale diagnostic tests are eligible for 3rd party reimbursement under already established medical billing codes * CPT Code 88361: Morphometric analysis, tumor immunohistochemistry, quantitative or semi-quantitative, each antibody; using computer-
Slide 18: Regulatory Pathway
Regulatory Pathway Two Pathways to Market * Lab Derived Test (LOT) regulated under CLIA (Clinical Laboratory Improvement Amendments); * In vitro Diagnostic (IVD) regulated by FDA, 510(k) submission and approval. Preferred Approach is to Offer LDT from Central Laboratory * Faster to market, less cost
Slide 19: MetaStat has Strong IP Positions
MetaStat has Strong IP Positions Broad Intellectual Property Position; * 12 patents filed; * 3 US core patents issued LOE - 2030 ¥ 8,642,277 -02/08/2014 ¥ 8,603,738 ~ 12/10/2013 8,298,756 — 10/30/2013 Amster, Rothstein, and Ebenstein, LLP & Morgan, Lewis, and Bockius, LLP Oversee our Patent Portfoli
Slide 20: Compelling Story: Positive Press Coverage
Compelling Story: Positive Press Coverage Boston = din Cancer agosto Removing sere estes sty thatthe technology will be able to predict i breast cancer will th e ‘swo rd iW of Damocles’ Medical Device Daily Mesos bee yea tot ‘most breast cancer patients NewCo on the Go: MetaStat's summer: new financ
Slide 21: Back-up Slides
Back-up Slides @MetaStat
Slide 22: Comparable Company Analysis MC/Rev Model
Comparable Company Analysis MC/Rev Model Comparable Diagnostic Companies + Average market cap $467M, range ($12M-$2,995M); + Average market cap/revenue 20.3 ($25.2 rev<$50M), range (1.7-90.7); + Each market share point is worth $2.7M or $68M in market cap. iE ret ee: o a a a” ee ee te ioc a a 2 @Met
Slide 23: Initial Market Opportunity - $271 million
Initial Market Opportunity - $271 million “Total Breast Cancer Market 2014 ‘Addressable Patient Population All other Subtypes 232,570 patients > 186,136 patients >| 74st parents $338 milion $271 milion $108 milion ‘One share pont ofthe addressable market is worth $27 millon based ‘om estimated avera
Slide 24: Diagnostic Tests Across the Patient Journey
Diagnostic Tests Across the “Patient Journey” Test for BRCAT, BRCAZ, PALB2 gene mutations Epigenetic melas isk deeminaon sacar cts etaSite Brees, MenaCale (MetaStat (Myriad Genetics) Gene panet-based risk of recur Ona te (Go ‘ gen , wanna cae Endoprdit® (Myra) MRI, Utrasound ete) Ful esse nu oftumor
Slide 25: Metastatic Cancer Cell Opening the Blood Vessel Wall
Metastatic Cancer Cell Opening the Blood Vessel Wall Metastatic cancer cell escape @MetaStat
Slide 26: The MetaSite: Capturing the Tumor MicroEnvironment
The MetaSite: Capturing the Tumor MicroEnvironment ‘The Window or Portal Where Systemic Metastasis Takes Place: Three cells in apposition + Red Metastatic Cell (Mena +) — Pan-Mena MAB + Blue Endothelial Cell — CD31 MAB + Brown Macrophage CD68MAB_/ Triple Immunohistochemical Stain @MetaStat
Slide 27: Encouraging Clinical Validation Studies
Encouraging Clinical Validation Studies * 3 positive clinical studies consisting of a total of 585 patients; * 481 patient study published in Journal of the National Cancer Institute*; MetaSite Breast Highly prognostic for ER+, HER2- (~60% of all breast cancer patients); + Smaller intermediate risk
Slide 28: Significance of Clinical Studies
Significance of Clinical Studies Toronto study designed to determine if MenaCalc can be used as independent prognostic marker for axillary node negative patients regardless of molecular sub-type. Higher MenaCalc was associated with decreased overall survival in both uni-variate (p=0.024) and multi-v